Plain-English translation of NCT07400354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether a combination of nivolumab, sintilimab, tislelizumab, or pembrolizumab (medicines that help your immune system fight cancer) works better when given alongside standard chemotherapy for advanced stomach cancer. Researchers also want to understand whether the bacteria in your gut can predict who will respond best to this treatment combination.
Advanced stomach cancer is hard to treat, and doctors need better first-line treatment options. This medication works by helping your body's immune system recognize and attack cancer cells, and early evidence suggests it may work better alongside chemotherapy. Researchers also believe your gut bacteria might be a clue about whether this treatment will help you personally.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy (one of three regimens chosen by your doctor) combined with an immune-boosting medication as your first treatment for advanced stomach cancer. Over the course of your treatment, you will have your gut bacteria sampled three times: before your first dose, before your third chemotherapy cycle, and after your sixth cycle or if disease progression occurs. Your doctor will monitor your response to treatment and adjust your care as needed throughout the study.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China